Navigation Links
Arpida Announces Full Year 2008 Financial Results
Date:2/25/2009

n-process R&D. In addition, the company restructuring which was announced in November 2008, has led to several adjustments in balance sheet values of assets and liabilities. More information can be found in the Notes to the Financial Statements in the 2008 Annual Report.

Statutory Accounts

Since inception, Arpida has chosen to capitalise research and development costs in its Statutory Accounts. In light of the announced company restructuring and the sharply reduced market capitalisation, this policy was reviewed. It was decided to write down 100% of the capitalised R&D expenses, resulting in an impairment charge in the Statutory Accounts. This does not impact the consolidated accounts, as R&D was never capitalised in these.

Outlook

After completion of the restructuring that was initiated at the end of 2008, the burn rate is expected to fall to around CHF 1 million on average per month from the second quarter of 2009 onwards. Cash and financial investments are expected to be around CHF 17 million at year-end 2009.

Pipeline Development

Intravenous iclaprim in cSSSI - setback in regulatory process

In 2008, regulatory filings for intravenous iclaprim in complicated skin and skin structure infections (cSSSI) were submitted in the USA, the European Union and in Canada.

On 20 November 2008, the Anti-infective Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted 17 to 2 against the approval of intravenous iclaprim for use in the treatment of patients with cSSSI. In January 2009, Arpida received the FDA's Complete Response Letter. The FDA indicated in its letter that they could not approve the application for intravenous iclaprim in its current form and required additional clinical data to demonstrate efficacy in order to gain approval. Arpida has initiated a dialogue with external experts and the FDA to develo
'/>"/>

SOURCE Arpida Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 According ... Market by Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), ... Labs, Research Institutes) - Analysis & Global Forecast ... the global Antibody Production Market for the forecast ... expected to reach $2.572 Billion by 2019 from ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... Va. , April 30, 2015 Oxford ... senior debt to life sciences and healthcare services companies, ... secured term loan agreement with Celula, Inc., a diagnostic ... major diseases, enabling better patient care and improved outcomes. ... the development and expand the commercialization of its products ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015 /PRNewswire/ ... company engaged in the development of biosimilar therapeutics ... today announced the closing of its previously announced ... common stock at a public offering price of ... full by the underwriters of their option to ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Oxford Finance Provides $10 Million Debt Financing to Celula 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... DEERFIELD, Ill., Dec. 3 Today, the International Society,for ... stem cell researchers, released new guidelines for the responsible,development ... A,Commentary article that summarizes the Guidelines for the ... Press in the December issue of Cell,Stem Cell, the ...
... 3 NeoStem, Inc.,(NYSE Alternext US: NBS), which is pioneering ... for future medical need,today announced that it has completed an ... priced at $1.25 per unit with each unit,consisting of one ... share of,common stock at $1.75 per share. , ...
... 3 The William Lehman Injury Research,Center ... at the, University of Miami /Jackson Medical ... and Advanced Technology Research Center (TATRC); the ... Association (ATA) and,Qualcomm, through its Wireless Reach(TM) ...
Cached Biology Technology:The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 2The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 3The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 4NeoStem Completes $500,000 Private Placement With Strategic Investor 2NeoStem Completes $500,000 Private Placement With Strategic Investor 3Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 2Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 3Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 4Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 5Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 6
(Date:4/2/2015)... 2015 Fingerprint Cards (FPC) has ... from the distributor World Peace Industrial Group (WPI), part ... although the major part of the shipments will take ... by smartphone manufacturers in China . ... the communicated revenue guidance of + 1 000 MSEK for ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... living cell needs both to build new and to ... number of intracellular systems work in concert to keep ... proteins. When proteins or peptides mutate, they can present ... environment. In Huntington's disease (HD) the disease provoking mutation ...
... international group of scientists has announced a major ... the activities of genes in living organisms. ... to describe the complex events that occur when ... Understanding these events is crucial for developing new ...
... they won't be able to understand the brain until they ... billions of neurons are interconnected. Now, researchers at the Salk ... be a major hurdle to preparing that chart: identifying all ... March 1 issue of the journal Neuron, the researchers describe ...
Cached Biology News:Proteasome activator enhances survival of Huntington's disease neuronal model cells 2Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3Deconstructing brain wiring, one neuron at a time 2Deconstructing brain wiring, one neuron at a time 3